FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy.

Animals Antineoplastic Agents / pharmacology Cisplatin / pharmacology Disease Models, Animal Drug Resistance, Neoplasm Female Focal Adhesion Kinase 1 / metabolism Humans Mice Ovarian Neoplasms / drug therapy Platinum / pharmacology Proto-Oncogene Proteins c-myc / metabolism Proto-Oncogene Proteins p21(ras) / metabolism Signal Transduction Stem Cells

beta-catenin cancer biology focal adhesion kinase FAK mouse ovarian cancer platinum chemotherapy pluripotency tumorspheres

Journal

eLife

ISSN: 2050-084X

Titre abrégé: Elife

Pays: England

ID NLM: 101579614

Informations de publication

Date de publication:
03 09 2019

Historique:

received: 03 04 2019

accepted: 01 08 2019

entrez: 4 9 2019

pubmed: 4 9 2019

medline: 20 2 2020

Statut: epublish

Résumé

Gene copy number alterations, tumor cell stemness, and the development of platinum chemotherapy resistance contribute to high-grade serous ovarian cancer (HGSOC) recurrence. Stem phenotypes involving Wnt-β-catenin, aldehyde dehydrogenase activities, intrinsic platinum resistance, and tumorsphere formation are here associated with spontaneous gains in

Identifiants

DOI: 10.7554/eLife.47327 PMID: 31478830 PMC: PMC6721800

pubmed: 31478830

doi: 10.7554/eLife.47327

pii: 47327

pmc: PMC6721800

doi:

pii:

Substances chimiques

Antineoplastic Agents 0

KRAS protein, human 0

MYC protein, human 0

Proto-Oncogene Proteins c-myc 0

Platinum 49DFR088MY

Focal Adhesion Kinase 1 EC 2.7.10.2

PTK2 protein, human EC 2.7.10.2

Proto-Oncogene Proteins p21(ras) EC 3.6.5.2

Cisplatin Q20Q21Q62J

Banques de données

SRA

['SRP194638']

GEO

['GSE129099']

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

Subventions

Organisme : NIH HHS

ID : UL1 TR001442

Pays : United States

Organisme : NIH HHS

ID : RO1 CA102310

Pays : United States

Organisme : NIH HHS

ID : RO1 CA180769

Pays : United States

Organisme : NIH HHS

ID : T32 CA121938

Pays : United States

Organisme : NIH HHS

ID : RO1 CA195723

Pays : United States

Organisme : Medical Research Council of Hungary

ID : KH-129581

Pays : International

Organisme : NCI NIH HHS

ID : R01 CA247562

Pays : United States

Organisme : United States Department of Defense

ID : W81XWH-19-1-0134

Pays : International

Organisme : NIH HHS

ID : P30 CA006927

Pays : United States

Organisme : NCI NIH HHS

ID : P30 CA006927

Pays : United States

Organisme : United States Department of Defense

ID : W81XWH-16-1-0142

Pays : International

Organisme : Medical Research Council of Hungary

ID : 2018-1.3.1-VKE-2018-00032

Pays : International

Organisme : NIH HHS

ID : RO1 CA107263

Pays : United States

Organisme : Medical Research Council of Hungary

ID : NVKP_16-1-2016-0037

Pays : International

Organisme : NIH HHS

ID : P30 CA023100

Pays : United States

Organisme : NIH HHS

ID : T36 GM095349

Pays : United States

Informations de copyright

Déclaration de conflit d'intérêts

CD, DO, EK, KT, AB, SJ, LB, FS, CJ, IT, KA, SU, EC, JL, XC, GF, MO, PR, JH, AM, GX, KF, BG, MM, DC, AM, DS, DS No competing interests declared, VK Former employee at Verastem Inc, DW, JP employee of Verastem Inc

Références

Gynecol Oncol. 2006 Jun;101(3):507-19

pubmed: 16387351

Nat Rev Dis Primers. 2016 Aug 25;2:16061

pubmed: 27558151

Nat Commun. 2013;4:2126

pubmed: 23839242

Proc Natl Acad Sci U S A. 1999 Apr 27;96(9):4947-52

pubmed: 10220399

BMC Cancer. 2014 Nov 18;14:837

pubmed: 25408231

Clin Exp Metastasis. 2013 Jun;30(5):579-94

pubmed: 23275034

Cell. 2018 Apr 5;173(2):338-354.e15

pubmed: 29625051

Oncogenesis. 2017 Jan 30;6(1):e295

pubmed: 28134933

BMC Cancer. 2016 Nov 22;16(1):913

pubmed: 27876019

Trends Mol Med. 2017 Apr;23(4):310-319

pubmed: 28279624

Mol Cancer Ther. 2018 Apr;17(4):806-813

pubmed: 29167314

Bioinformatics. 2009 Jul 15;25(14):1754-60

pubmed: 19451168

Nat Rev Mol Cell Biol. 2005 Jan;6(1):56-68

pubmed: 15688067

Oncotarget. 2017 May 16;8(20):33972-33989

pubmed: 28430641

Cancer Discov. 2012 Jan;2(1):56-67

pubmed: 22328975

Oncotarget. 2017 Jun 16;8(31):51733-51747

pubmed: 28881682

Carcinogenesis. 2000 Apr;21(4):585-91

pubmed: 10753190

Gynecol Oncol. 2014 Feb;132(2):483-9

pubmed: 24321398

J Cell Sci. 2012 Jan 15;125(Pt 2):449-60

pubmed: 22302992

Cancer Res. 2016 Dec 1;76(23):6964-6974

pubmed: 27671674

Mol Cancer Ther. 2014 Aug;13(8):2050-61

pubmed: 24899686

Cancer Res. 2011 Jun 1;71(11):3991-4001

pubmed: 21498635

Nature. 2011 Jun 29;474(7353):609-15

pubmed: 21720365

Nature. 2015 May 28;521(7553):489-94

pubmed: 26017449

Genome Res. 2010 Sep;20(9):1297-303

pubmed: 20644199

Oncogene. 2019 Sep;38(36):6323-6337

pubmed: 31308489

Int J Cancer. 2012 Jul 15;131(2):287-97

pubmed: 21823119

Dev Cell. 2010 Aug 17;19(2):259-69

pubmed: 20708588

CA Cancer J Clin. 2018 Jan;68(1):7-30

pubmed: 29313949

Prostate. 2018 Jun;78(8):583-594

pubmed: 29520855

Nat Rev Cancer. 2015 Nov;15(11):668-79

pubmed: 26493647

Sci Rep. 2017 Dec 4;7(1):16827

pubmed: 29203787

Proc Natl Acad Sci U S A. 2019 Jan 8;116(2):619-624

pubmed: 30584090

Sci Signal. 2017 Dec 05;10(508):

pubmed: 29208683

Oncotarget. 2015 Sep 15;6(27):23720-34

pubmed: 26125441

Cell. 2016 Jul 28;166(3):755-765

pubmed: 27372738

Front Cell Dev Biol. 2017 Feb 03;5:7

pubmed: 28217689

J Natl Cancer Inst. 2013 Oct 2;105(19):1485-95

pubmed: 24062525

Ann Oncol. 2016 Dec;27(12):2268-2274

pubmed: 27733373

Prostate. 2018 Mar;78(4):308-317

pubmed: 29314097

Curr Opin Cell Biol. 2017 Apr;45:24-30

pubmed: 28213315

Nucleic Acids Res. 2010 Sep;38(16):e164

pubmed: 20601685

Oncotarget. 2016 May 24;7(21):30511-22

pubmed: 27105520

PLoS Comput Biol. 2016 Apr 21;12(4):e1004873

pubmed: 27100738

Nat Genet. 2010 Oct;42(10):874-9

pubmed: 20852632

Cancer Res. 2014 Jul 1;74(13):3579-90

pubmed: 24812274

Elife. 2015 Sep 03;4:

pubmed: 26274564

Genes (Basel). 2017 Jun 07;8(6):

pubmed: 28590415

Endocr Relat Cancer. 2012 Apr 10;19(2):197-208

pubmed: 22277193

Invest New Drugs. 2015 Oct;33(5):1100-7

pubmed: 26334219

Cancer Res. 2016 Oct 15;76(20):6118-6129

pubmed: 27530326

Nat Rev Clin Oncol. 2016 Apr;13(4):255-61

pubmed: 26787282

Nucleic Acids Res. 2019 Jan 8;47(D1):D442-D450

pubmed: 30395289

J Clin Invest. 2016 May 2;126(5):1885-96

pubmed: 27064283

J Biol Chem. 2010 Jul 9;285(28):21526-36

pubmed: 20442405

Mol Cell. 2008 Jan 18;29(1):9-22

pubmed: 18206965

Cancer Biol Ther. 2010 May 15;9(10):764-77

pubmed: 20234191

Cancer Discov. 2018 Mar;8(3):304-319

pubmed: 29196464

Cancer Lett. 2019 May 28;450:132-143

pubmed: 30849480

Hepatology. 2019 Nov;70(5):1631-1645

pubmed: 31069844

Nat Rev Cancer. 2014 Sep;14(9):598-610

pubmed: 25098269

Trends Cancer. 2017 Feb;3(2):137-148

pubmed: 28718444

Nat Biotechnol. 2011 Jan;29(1):24-6

pubmed: 21221095

Dev Cell. 2012 Jan 17;22(1):146-57

pubmed: 22264731

Mol Cancer Ther. 2015 Mar;14(3):747-56

pubmed: 25589495

Genome Biol. 2013 Apr 25;14(4):R36

pubmed: 23618408

Elife. 2019 Sep 03;8:

pubmed: 31478830

Oncogene. 2015 Apr 30;34(18):2297-308

pubmed: 24954508

Cell. 2018 Apr 5;173(2):321-337.e10

pubmed: 29625050

Oncogenesis. 2018 Feb 23;7(2):21

pubmed: 29472531

PLoS One. 2010 Sep 10;5(9):

pubmed: 20844748

FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy.

Journal

Informations de publication

Résumé

Identifiants

Substances chimiques

Banques de données

Types de publication

Langues

Sous-ensembles de citation

Subventions

Informations de copyright

Déclaration de conflit d'intérêts

Références

Auteurs

Articles similaires

Classifications MeSH